00:43 , Apr 19, 2019 |  BC Week In Review  |  Clinical News

LineaRx produces CAR T cells via non-viral, plasmid-free platform

LineaRx said its non-viral, plasmid-free manufacturing platform was able to induce anti-CD19 CAR expression in human T cells. The platform uses PCR manufacturing to create a linear DNA amplicon encoding anti-CD19, which is then electroporated...
08:00 , Nov 6, 2006 |  BC Week In Review  |  Company News

Odyssey board of directors update

Odyssey Thera Inc. , San Ramon, Calif.   Business: Cancer   Appointed: Hugh Rienhoff, former CEO of DNA Sciences Inc.  ...
07:00 , Oct 19, 2004 |  BC Extra  |  Company News

NeoRx names Berland CFO

Cancer company NeoRx (NERX) hired Susan Berland as CFO. Most recently, Berland served as an industry consultant. She previously was CFO of DNA Sciences , which was acquired by Genaissance (GNSC). NERX's Skeletal Targeted Radiotherapy...
07:00 , May 3, 2004 |  BC Week In Review  |  Company News

Genaissance, University of Utah, Yale University deal

GNSC amended its license agreement with the universities, under which the company has rights to five cardiac ion channel genes. GNSC said the new deal terms simplify the royalty structure on its test for cardiac...
08:00 , Mar 1, 2004 |  BC Week In Review  |  Company News

Lynx management update

Lynx Therapeutics Inc. (LYNX), Hayward, Calif.   Business: Genomics, Proteomics   Departed: Edward Albini as CFO   Hired: Susan Berland as interim CFO, formerly CFO at DNA Sciences Inc.  ...
07:00 , Apr 7, 2003 |  BC Week In Review  |  Company News

DNA Sciences, Genaissance deal

GNSC will acquire the assets of DNA Sciences for $1.3 million in cash and stock. DNA Sciences, which has filed for Chapter 11 bankruptcy protection, will seek bankruptcy court approval for a pre-negotiated asset purchase...
08:00 , Apr 1, 2003 |  BC Extra  |  Company News

GNSC to acquire DNA Sciences' assets

Pharmacogenetics company Genaissance (GNSC) will acquire the assets of DNA Sciences (Fremont, Calif.) for $1.3 million in cash and stock. DNA Sciences on Tuesday filed for Chapter 11 bankruptcy protection. GNSC said the acquisition adds...
07:00 , Oct 21, 2002 |  BC Week In Review  |  Company News

DNA Sciences, Prometheus deal

Prometheus received a co-exclusive sublicense to DNA Sciences's patent covering diagnostics that detect two alleles of the gene for thiopurine s-methyltransferase (TPMT) . The alleles are associated with deficiencies in production of the enzyme, which...
07:00 , Sep 9, 2002 |  BC Week In Review  |  Company News

DNA Sciences, Merck KGaA deal

The companies partnered to research and identify DNA variants that may modify responses to medications in diverse ethnic groups. The companies will research gene variants and test allele frequencies in three separate ethnic groups to...
07:00 , Jul 22, 2002 |  BioCentury  |  Finance

Ebb & Flow

With bushel baskets of VC money chasing product companies, it's not surprising that some valuations are getting overcooked. Now some VCs are putting their money to work in select toolkit companies, because their valuations are...